The Journal of Contemporary Dental Practice

Register      Login

SEARCH WITHIN CONTENT

FIND ARTICLE

Volume / Issue

Online First

Archive
Related articles

VOLUME 17 , ISSUE 3 ( March, 2016 ) > List of Articles

RESEARCH ARTICLE

Effect of Addition of Platelet-rich Plasma to Calcium Phosphosilicate Putty on Healing at 9 Months in Periodontal Intrabony Defects

Ashi Chug, Harpreet Singh Grover, Lanka Mahesh, Sagrika Shukla

Citation Information : Chug A, Grover HS, Mahesh L, Shukla S. Effect of Addition of Platelet-rich Plasma to Calcium Phosphosilicate Putty on Healing at 9 Months in Periodontal Intrabony Defects. J Contemp Dent Pract 2016; 17 (3):230-234.

DOI: 10.5005/jp-journals-10024-1832

Published Online: 00-03-2016

Copyright Statement:  Copyright © 2016; Jaypee Brothers Medical Publishers (P) Ltd.


Abstract

Background and objective

Combination of platelet-rich plasma (PRP) and bone substitutes for the surgical treatment of periodontal intrabony defects is based on a sound biologic rationale; however, the clinical results indicative of the synergistic effect of PRP remain ambiguous. The objective of the present study was to clinically and radiographically evaluate the use of calcium phosphosilicate (CPS) putty alone and in combination with PRP in the treatment of periodontal intrabony defects.

Materials and methods

The study was performed at an outpatient facility at a teaching dental institute in north India. A split-mouth design was employed to assess the clinical parameters and radiographic bone fill following the use of CPS putty with and without PRP in patients scheduled for surgical periodontal treatment of intrabony osseous defects. Each defect was randomized to receive treatment with open flap debridement, with CPS putty alone (Group PUT), or open flap debridement with CPS putty and PRP (Group PRP). Probing pocket depth (PPD), plaque index (PI), gingival index (GI), and clinical attachment levels (CALs) were recorded at the investigated sites utilizing custom-made reference guides for measurement reproducibility. Standardized periapical radiographs were also obtained to evaluate defect fill at the surgical sites.

Results

Twenty patients each with at least two defects located in different quadrants were enrolled. The reduction in PPD from baseline to 1st, 3rd, 6th, and 9th month was found to be significant (p < 0.05). The percent reduction in PPD among PUT group was 57.18 ± 10.71% and among PRP group was 51.39 ± 12.60%. No statistically significant difference was observed in the percent reduction in PPD among two groups at 9 months (p = 0.48). Sites in both groups exhibited statistically significant reductions in PI and GI that were maintained throughout the study period. Similar results were seen while measuring CAL.

Conclusion

Calcium phosphosilicate Putty alone provides significant improvement in outcomes for the treatment of periodontal intraosseous defects. The addition of PRP to CPS putty does not seem to provide any additive benefit to treatment and the additional surgical time and trauma can be avoided.

How to cite this article

Shukla S, Chug A, Mahesh L, Grover HS. Effect of Addition of Platelet-rich Plasma to Calcium Phosphosilicate Putty on Healing at 9 Months in Periodontal Intrabony Defects. J Contemp Dent Pract 2016;17(3):230-234.


PDF Share
  1. Platelet-derived growth factor stimulates bone fill and rate of attachment level gain: results of a large multicenter randomized controlled trial. J Periodontol 2005 Dec;76(12):2205-2215.
  2. Practical application of the newly introduced natural bone regeneration (NBR) concept utilizing alloplastic Putty. Int J Oral Implantol Clin Res 2011;2:145-149.
  3. Alveolar ridge preservation with the socket-plug technique utilizing an alloplastic putty bone substitute or a particulate xenograft: a histological pilot study. J Oral Implantol 2015 Apr;41(2):178-183.
  4. A minimally invasive sinus augmentation technique using a novel bone graft delivery system. Int J Oral Implantol Clin Res 2013;4:78-82.
  5. Platelet-derived growth factor stimulates bone fill and rate of attachment level gain: results of a large multicenter randomized controlled trial. J Periodontol 2005 Dec;76(12):2205-2215.
  6. Longterm clinical results on the use of platelet concentrate in the treatment of intrabony periodontal defects. Acta Odontol Scand 2014 Feb;72(2):92-98.
  7. Human histologic evaluation of the use of the dental putty for bone formation in the maxillary sinus: case series. J Oral Implantol 2012 Aug;38(4):391-398.
  8. Periodontol disease is pregnancy and co-relation between oral hygiene and periodontal conditions. Acta Odontol Scand 1964;24:747-759.
  9. Periodontal diseases in pregnancy. Prevalence and severity. Acta Odontol Scand 1963 Dec;21:533-551.
  10. Enamel matrix derivative versus bioactive ceramic filler in the treatment of intrabony defects: 12-month results. J Periodontol 2009 Feb;80(2):219-227.
  11. Synthetic bone graft particles and open debridement in the treatment of human periodontal defects. A clinical study. J Periodontol 1998 Jun:69(6):698-709.
  12. Clinical evaluation of bioactive glass in the treatment of periodontal osseous defects in humans. J Periodontol 1998 Sep;69(9):1027-1035.
  13. The story of bioglass. J Mater Sci Mater Med 2006 Nov;17(11):967-978.
  14. Quantitative comparison of bone growth behavior in granules of Bioglass, A-W glass-ceramic, and hydroxyapatite. J Biomed Mater Res 2000 Jul;51(1):37-46.
  15. Geneexpression profiling of human osteoblasts following treatment with the ionic products of Bioglass 45S5 dissolution. J Biomed Mater Res 2001 May;55(2):151-157.
  16. Ionic products of bioactive glass dissolution increase proliferation of human osteoblasts and induce insulin-like growth factor II mRNA expression and protein synthesis. Biochem Biophys Res Commun 2000 Sep 24;276(2):461-465.
  17. An evaluation of bioactiveglass in the treatment of periodontal defects: a meta-analysis of randomized controlled clinical trials. J Periodontol 2012 Apr;83(4):453-464.
  18. Evaluation of a bioactive glass alloplast in treating periodontal intrabony defects. J Periodontol 1998 Dec;69(12):1346-1354.
  19. Effects of pretreatment clinical parameters on bioactive glass implantation in intrabony periodontal defects. J Periodontol 2001 Jun;72(6):730-740.
  20. Particulate bioglass as a grafting material in the treatment of periodontal intrabony defects. J Clin Periodontol 1997 Jun;24(6):410-418.
  21. Platelet-rich plasma: growth factor enhancement for bone grafts. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1998 Jun:85(6):638-646.
  22. Alveolar ridge and sinus augmentation utilizing platelet-rich plasma in combination with freeze dried bone allograft: case series. J Periodontol 2000 Oct;71(10):1654-1661.
  23. Platelet-rich plasma: evidence to support its use. J Oral Maxillofac Surg 2004 Apr;62(4):489-496.
  24. Platelet –rich plasma influence on human osteoblast growth. Clin Oral Implants Res 2005 Aug;16(4):256-460.
  25. Effects of activated platelet concentrates on human primary cultures of fibroblasts and osteoblasts. J Periodontol 2005 Mar;76(3):323-328.
  26. Effects of activated and nonactivated platelet-rich plasma on proliferation of human osteoblasts in vitro. J Oral Maxillofac Surg 2008 Feb;66(2):297-301.
  27. Determination of vascular endothelial growth factor (VEGF) in circulating blood: significance of VEGF in various leukocytes and platelets. Scand J Clin Lab Invest 2002;62(5):343-350.
  28. Effect of platelet-rich plasma on bone regeneration in autogenous bone graft. Int J Oral Maxillofac Surg 2004 Jan;33(1):56-59.
  29. Osseous defect regeneration using autogenous bone alone or combined with Biogran or Algipore with and without added thrombocytes. A microradiologic evaluation. Mund Kiefer Gesichtschir 2003 Mar;7(2):112-118.
  30. Imaging methods in periodontology. Periodontol 2000 2004;34:34-38.
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.